Dynavax Technologies Corp. logo

DVAX

Dynavax Technologies Corp.

$12.32

Earnings Summary

Revenue
$256.46Mn
Net Profits
$128.76Mn
Net Profit Margins
50.2%
PE Ratio
9.89

Highlights

Revenue:

Dynavax Technologies Corp.’s revenue jumped 386.03% since last year same period to $256.46Mn in the Q2 2022. On a quarterly growth basis, Dynavax Technologies Corp. has generated 124.98% jump in its revenue since last 3-months.

Net Profits:

Dynavax Technologies Corp.’s net profit jumped 2778.49% since last year same period to $128.76Mn in the Q2 2022. On a quarterly growth basis, Dynavax Technologies Corp. has generated 291.84% jump in its net profits since last 3-months.

Net Profit Margins:

Dynavax Technologies Corp.’s net profit margin jumped 492.24% since last year same period to 50.2% in the Q2 2022. On a quarterly growth basis, Dynavax Technologies Corp. has generated 74.16% jump in its net profit margins since last 3-months.

PE Ratio:

Dynavax Technologies Corp.’s price-to-earnings ratio after this Q2 2022 earnings stands at 9.89.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Dynavax Technologies Corp. post its latest quarter earnings

EPS Estimate Current Quarter
0.22
EPS Estimate Current Year
0.22

Highlights

EPS Estimate Current Quarter:

Dynavax Technologies Corp.’s earning per share (EPS) estimates for the current quarter stand at 0.22 - a -8.33% fall from last quarter’s estimates.

EPS Estimate Current Year:

Dynavax Technologies Corp.’s earning per share (EPS) estimates for the current year stand at 0.22.

Key Ratios

Key ratios of the Dynavax Technologies Corp. post its Q2 2022 earnings

Return on Assets (ROA)
0.2
Return on Equity (ROE)
0.92
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Dynavax Technologies Corp.’s return on assets (ROA) stands at 0.2.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Dynavax Technologies Corp.’s return on equity (ROE) stands at 0.92.

Dividend Per Share (DPS):

Dynavax Technologies Corp. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
0.24
0.22
-8.33%

Company Information

Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.

Organisation
Dynavax Technologies Corp.
Headquarters
Emeryville, California, US
Employees
245
Industry
Health Technology
CEO
Ryan Spencer